Group | Drug |
First-line oral | Isoniazid, Rifampicin, Ethambutol, Pyrazinamide, Rifabutin and Rifapentine |
Injectables | Streptomycin, Kanamycin, Amikacin and Capreomycin |
Fluoroquinolones | Levofloxacin, Moxifloxacin, Gatifloxacin and Ofloxacin |
Oral bacteriostatic second-line anti-TB drugs | Ethionamide, Prothionamide, Cycloserine, Terizidone, p-Aminosalicylic acid and p-Aminosalicylate sodium |
Anti-TB drugs with limited data on efficacy and/or long-term safety in the treatment of drug-resistant TB | Linezolid, Clofazimine, Amoxicillin/clavulanate, Imipenem/cilastatin, Meropenem, High-dose isoniazid, Thioacetazone, Clarithromycin, Bedaquiline and Delamanid |
Other drugs (need clinical trials) | Sulfamethoxazole, Mefloquine, Pretomanid, Sutezolid, SQ109 and Benzothiazinones |